Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015 (2015), Article ID 420159, 7 pages
http://dx.doi.org/10.1155/2015/420159
Case Report

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer

Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA

Received 19 February 2015; Revised 6 April 2015; Accepted 8 April 2015

Academic Editor: Jorg Kleeff

Copyright © 2015 Pashtoon Murtaza Kasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. Kasi, J. M. Hubbard, and A. Grothey, “Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers,” Expert Review of Gastroenterology & Hepatology, vol. 9, no. 3, pp. 273–276, 2015. View at Publisher · View at Google Scholar
  2. E. Raymond, V. Boige, S. Faivre et al., “Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4303–4312, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. H. Doroshow, T. W. Synold, D. Gandara et al., “Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group,” Seminars in Oncology, vol. 30, no. 4, pp. 14–19, 2003. View at Google Scholar · View at Scopus
  4. G. F. Fleming, R. L. Schilsky, L. P. Schumn et al., “Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfuntion,” Annals of Oncology, vol. 14, no. 7, pp. 1142–1147, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Shitara, D. Takahari, T. Yokota et al., “Case Series of cetuximab monotherapy for patients with pre-treated colorectal cancer complicated with hyperbilirubinemia due to severe liver metastasis,” Japanese Journal of Clinical Oncology, vol. 40, no. 3, pp. 275–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. G. Fakih, “5-Fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction,” Oncology, vol. 67, no. 3-4, pp. 222–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Elsoueidi, J. Craig, H. Mourad, and E. M. Richa, “Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction,” Journal of the National Comprehensive Cancer Network, vol. 12, pp. 155–160, 2014. View at Google Scholar
  8. T. Shimura, H. Kataoka, Y. Hirata et al., “Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy,” Journal of Gastrointestinal Cancer, vol. 42, no. 1, pp. 68–72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Grenader, A. Goldberg, and A. Gabizon, “Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel,” Anti-Cancer Drugs, vol. 20, no. 9, pp. 845–847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Yoshino, N. Mizunuma, K. Yamazaki et al., “TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial,” The Lancet Oncology, vol. 13, no. 10, pp. 993–1001, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Chong, J. L. B. Dickson, D. Cunningham et al., “Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan,” British Journal of Cancer, vol. 93, no. 5, pp. 510–514, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. E. Caudle, C. F. Thorn, T. E. Klein et al., “Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing,” Clinical Pharmacology and Therapeutics, vol. 94, no. 6, pp. 640–645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Adrucil [Package Insert], Teva Parental Medicines, Irvine, Calif, USA, 2007.
  14. Eloxatin [Package Insert], Ben Venue Laboratories, Cleveland, Ohio, USA, 2011.
  15. M. Baur, A. Drescher, M. Gneist, C. Dittrich, and U. Jaehde, “Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction,” Cancer Chemotherapy and Pharmacology, vol. 61, no. 1, pp. 97–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. W. Synold, C. H. Takimoto, J. H. Doroshow et al., “Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a national cancer institute organ dysfunction working group study,” Clinical Cancer Research, vol. 13, no. 12, pp. 3660–3666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Camptosar [Package Insert], Pfizer, New York, NY, USA, 2014.
  18. C. J. van Groeningen, W. J. F. van der Vijgh, J. J. Baars, H. Stieltjes, K. Huibregtse, and H. M. Pinedo, “Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines,” Clinical Cancer Research, vol. 6, no. 4, pp. 1342–1346, 2000. View at Google Scholar · View at Scopus
  19. A. P. Venook, C. E. Klein, G. Fleming et al., “A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863,” Annals of Oncology, vol. 14, no. 12, pp. 1783–1790, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. TAS-102: Investigator's Brochure Version G 5.0 14, Taiho Pharmaceutical, Tokyo, Japan, 2014.
  21. STIVARGA (Package Insert), Bayer Healthcare, 2014.